In addition, the application of immunohistochemical technology had also identified a series of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) markers, such as EGFR and ALK mutation testing to refine particular subtypes of NSCLC classification [10]. This evidence concerns the gene ALK and non-small cell lung carcinoma.